^
Association details:
| Biomarker: | EGFR mutation + BRCA1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
Published date:
10/23/2020
Excerpt:
We evaluated the impact of BRCA1 mRNA expression in 91 patients with EGFR-mutant NSCLC….For patients with high BRCA1 mRNA expression (BRCA1-high group), median PFS was 12.9 months in the gefitinib plus olaparib arm, compared with 9.2 months in the gefitinib arm (p = 0.0449). In the gefitinib arm, median PFS was 9.1 months for the BRCA1-high group and 10.2 months for the BRCA1-low group (p = 0.0193).
DOI:
10.1016/j.jtocrr.2020.100113
Trial ID:
